Last reviewed · How we verify
Levetiracetam 250mg
At a glance
| Generic name | Levetiracetam 250mg |
|---|---|
| Also known as | Keppra |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (PHASE3)
- Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk (NA)
- An Investigation of Levetiracetam in Alzheimer's Disease (PHASE2)
- Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NA)
- Pharmacological Modulation of Hippocampal Activity in Psychosis 2 (PHASE2)
- Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy (PHASE4)
- Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) (PHASE2)
- Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levetiracetam 250mg CI brief — competitive landscape report
- Levetiracetam 250mg updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI